HRP20231692T1 - Postupak za suzbijanje gorčine derivata kinolina - Google Patents

Postupak za suzbijanje gorčine derivata kinolina Download PDF

Info

Publication number
HRP20231692T1
HRP20231692T1 HRP20231692TT HRP20231692T HRP20231692T1 HR P20231692 T1 HRP20231692 T1 HR P20231692T1 HR P20231692T T HRP20231692T T HR P20231692TT HR P20231692 T HRP20231692 T HR P20231692T HR P20231692 T1 HRP20231692 T1 HR P20231692T1
Authority
HR
Croatia
Prior art keywords
use according
suspension
quinolinecarboxyamide
cyclopropylaminocarbonyl
aminophenoxy
Prior art date
Application number
HRP20231692TT
Other languages
English (en)
Inventor
Kentaro Nagane
Yosuke Ueki
Shusuke Sano
Takahisa Sakaguchi
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56789022&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20231692(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of HRP20231692T1 publication Critical patent/HRP20231692T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Claims (13)

1. Upotreba bazične tvari odabrane između bazičnog oksida, bazičnog karbonata ili bazičnog hidroksida, poželjno kalcijevog karbonata ili magnezijevog oksida, i poželjnije kalcijevog karbonata, za suzbijanje gorčine 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida, ili njegove farmaceutski prihvatljive soli, poželjno njegovog mesilata, pri čemu je poželjno 0,01 do 50 težinskih dijelova bazične tvari pomiješano na 1 težinski dio 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli ili se 0,16 do 80 mola bazične tvari pomiješa na 1 mol 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli.
2. Upotreba prema zahtjevu 1 za suzbijanje gorčine 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida, ili njegove farmaceutski prihvatljive soli u farmaceutskom pripravku, koji sadrži 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli, poželjno njegovog mesilata, 0,01 do 50 težinskih dijelova bazične tvari na 1 težinski dio 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli, poželjno 0,16 do 80 mol bazične tvari po 1 molu 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli.
3. Upotreba prema zahtjevu 2, naznačena time što je farmaceutski pripravak u obliku doziranja koji je tableta koja se oralno raspada, pripravak za žvakanje, šumeća tableta, disperzibilna tableta, topive tableta, sirup, pripravak za sirup, pastila ili oralni tekući pripravak i poželjno je da to bude pripravak koji se može suspendirati u vodenom otapalu nakon primjene kako bi se pripremila suspenzija.
4. Upotreba prema bilo kojem od zahtjeva 1-3, naznačena time što je bazična tvar kalcijev karbonat ili magnezijev oksid.
5. Upotreba prema bilo kojem od zahtjeva 1-3, naznačena time što je bazična tvar kalcijev karbonat.
6. Suspenzija koja sadrži 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamid ili njegovu farmaceutski prihvatljivu sol, i bazičnu tvar za upotrebu u postupku za liječenje raka, te postupak uključuje: 1) suspendiranje farmaceutskog pripravka koji sadrži 1 do 24 mg 4-(3-klor-4-(ciklopropilaminokarbonil)aminofenoksi)-7-metoksi-6-kinolinkarboksiamida ili njegove farmaceutski prihvatljive soli, poželjno njegov mesilat, i bazičnu tvar koja je odabrana između bazičnog oksida, bazičnog karbonata ili bazičnog hidroksida, poželjno kalcijevog karbonata ili magnezijevog oksida, a poželjnije kalcijevog karbonata, u vodenom otapalu u posudi; 2) davanje iz posude suspenzije dobivene u 1) pacijentu; 3) ispiranje posude s vodenim otapalom; i 4) davanje pacijentu otopine za ispiranje dobivene u 3).
7. Suspenzija za upotrebu prema zahtjevu 6, pri čemu 1) naznačena time što 1) obuhvaća: i) izlijevanje vodenog otapala u posudu, ii) ostavljanje posude da stoji; i iii) protresanje posude.
8. Suspenzija za upotrebu prema zahtjevu 6 ili 7, naznačena time što je farmaceutski pripravak suspendiran u 1 do 10 mL vodenog otapala u 1).
9. Suspenzija za upotrebu prema zahtjevu 8, naznačena time što je farmaceutski pripravak suspendiran u oko 3 mL vodenog otapala u 1).
10. Suspenzija za upotrebu prema zahtjevu 6, naznačena time što se posuda ispire s 1 do 10 mL vodenog otapala u 3).
11. Suspenzija za upotrebu prema zahtjevu 10, naznačena time što se posuda ispire s oko 2 mL vodenog otapala u 3).
12. Suspenzija za upotrebu prema bilo kojem od zahtjeva 6-11, naznačena time što je bazična tvar kalcijev karbonat ili magnezijev oksid.
13. Suspenzija za upotrebu prema bilo kojem od zahtjeva 6-11, naznačena time što je bazična tvar kalcijev karbonat.
HRP20231692TT 2015-02-25 2016-02-23 Postupak za suzbijanje gorčine derivata kinolina HRP20231692T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562120561P 2015-02-25 2015-02-25
EP16755489.8A EP3263106B1 (en) 2015-02-25 2016-02-23 Method for suppressing bitterness of quinoline derivative
PCT/JP2016/055268 WO2016136745A1 (ja) 2015-02-25 2016-02-23 キノリン誘導体の苦味抑制方法

Publications (1)

Publication Number Publication Date
HRP20231692T1 true HRP20231692T1 (hr) 2024-03-15

Family

ID=56789022

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20231692TT HRP20231692T1 (hr) 2015-02-25 2016-02-23 Postupak za suzbijanje gorčine derivata kinolina

Country Status (23)

Country Link
US (2) US20180028662A1 (hr)
EP (1) EP3263106B1 (hr)
JP (1) JP6792546B2 (hr)
KR (1) KR20170122734A (hr)
CN (1) CN107427505A (hr)
AU (1) AU2016224583B2 (hr)
BR (1) BR112017017428A2 (hr)
CA (1) CA2976325C (hr)
DK (1) DK3263106T3 (hr)
ES (1) ES2967362T3 (hr)
FI (1) FI3263106T3 (hr)
HR (1) HRP20231692T1 (hr)
HU (1) HUE064614T2 (hr)
IL (1) IL253946A0 (hr)
LT (1) LT3263106T (hr)
MX (1) MX2017010474A (hr)
PL (1) PL3263106T3 (hr)
PT (1) PT3263106T (hr)
RS (1) RS65049B1 (hr)
RU (1) RU2017128583A (hr)
SG (1) SG11201706630UA (hr)
SI (1) SI3263106T1 (hr)
WO (1) WO2016136745A1 (hr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200345637A1 (en) * 2018-01-19 2020-11-05 Aiviva Biopharma, Inc. Suspension compositions of multi-target inhibitors
CN112190583B (zh) * 2019-07-08 2021-10-29 成都苑东生物制药股份有限公司 一种乐伐替尼药物组合物及其制备方法
US20230158012A1 (en) * 2020-05-23 2023-05-25 Shilpa Medicare Ltd Oral liquid formulations of lenvatinib

Family Cites Families (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB1458148A (en) 1974-04-19 1976-12-08 Wyeth John & Brother Ltd Carbocyclic-fused ring quinoline derivatives
JPS57123267A (en) 1981-01-23 1982-07-31 Kansai Paint Co Ltd Thermosetting paint composition
SE8103843L (sv) 1981-06-18 1982-12-19 Astra Laekemedel Ab Farmaceutisk mixtur
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
EP0154434B1 (en) 1984-02-17 1993-01-27 Genentech, Inc. Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
DE8411409U1 (de) 1984-04-11 1984-08-30 Dr.-Ing. Walter Frohn-Betriebe, 8000 München Entgasungsventil fuer lager- und/oder transportbehaelter
US4563417A (en) 1984-08-31 1986-01-07 Miles Laboratories, Inc. Nucleic acid hybridization assay employing antibodies to intercalation complexes
DE3474040D1 (en) 1984-11-22 1988-10-20 Holsten Brauerei Ag Beer and process for its preparation
EP0184365B1 (en) 1984-12-04 1993-08-04 Eli Lilly And Company Improvements in the treatment of tumors in mammals
JPS61148115A (ja) 1984-12-21 1986-07-05 Tooa Eiyoo Kk 難溶性薬物の徐放性製剤及びその製造法
JPS62168137A (ja) 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
CH656535A5 (en) 1986-01-24 1986-07-15 Spirig Ag Process for the production of stable pharmaceutical tablets which disintegrate rapidly in water
JPH07106295B2 (ja) 1986-07-22 1995-11-15 エーザイ株式会社 調湿剤
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
US5009894A (en) 1988-03-07 1991-04-23 Baker Cummins Pharmaceuticals, Inc. Arrangement for and method of administering a pharmaceutical preparation
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US4983615A (en) 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
EP0408496A3 (en) 1989-07-12 1992-07-01 Ciba-Geigy Ag Solid dosage form for pharmaceutical substances
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
DK0834575T3 (da) 1990-12-06 2002-04-02 Affymetrix Inc A Delaware Corp Identifikation af nucleinsyrer i prøver
GB9105677D0 (en) 1991-03-19 1991-05-01 Ici Plc Heterocyclic compounds
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH04341454A (ja) 1991-05-16 1992-11-27 Canon Inc シート収納装置
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5211951A (en) 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
JPH05194259A (ja) * 1991-08-30 1993-08-03 Mitsubishi Kasei Corp 抗消化性潰瘍剤
US5200194A (en) 1991-12-18 1993-04-06 Alza Corporation Oral osmotic device
WO1993024627A1 (en) 1992-06-03 1993-12-09 Case Western Reserve University Bandage for continuous application of biologicals
TW271400B (hr) * 1992-07-30 1996-03-01 Pfizer
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JPH06153952A (ja) 1992-11-26 1994-06-03 Nobuaki Tamamaki 微量未知二重鎖ｄｎａ分子の増幅、標識を行うための前処理方法
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JP3254219B2 (ja) 1993-01-19 2002-02-04 ワーナー−ランバート・コンパニー 安定な経口用のｃｉ−９８１製剤およびその製法
US6027880A (en) 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
JPH07176103A (ja) 1993-12-20 1995-07-14 Canon Inc 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
GB9326136D0 (en) 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
JP3660391B2 (ja) 1994-05-27 2005-06-15 株式会社東芝 半導体装置の製造方法
JPH0848078A (ja) 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd 感熱記録体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5656454A (en) 1994-10-04 1997-08-12 President And Fellows Of Harvard College Endothelial cell-specific enhancer
JP3207058B2 (ja) 1994-11-07 2001-09-10 財団法人国際超電導産業技術研究センター 超電導体薄膜及びその製造方法
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
JPH08176138A (ja) 1994-12-19 1996-07-09 Mercian Corp イソクマリン誘導体
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5658374A (en) 1995-02-28 1997-08-19 Buckman Laboratories International, Inc. Aqueous lecithin-based release aids and methods of using the same
US5624937A (en) 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
EP3103799B1 (en) 1995-03-30 2018-06-06 OSI Pharmaceuticals, LLC Quinazoline derivatives
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5654005A (en) 1995-06-07 1997-08-05 Andrx Pharmaceuticals, Inc. Controlled release formulation having a preformed passageway
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
JPH0923885A (ja) 1995-07-12 1997-01-28 Dai Ichi Seiyaku Co Ltd 遺伝子発現ライブラリー及びその製造法
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
DE69622183D1 (de) 1995-11-07 2002-08-08 Kirin Brewery Chinolinderivate und chinazolinderivate welche die autophosphorylierung des von blutplättchen abstammenden wachstumsfaktorrezeptors inhibiren und sie enthaltende pharmazeutische zusammensetzungen
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
JPH09234074A (ja) 1996-03-04 1997-09-09 Sumitomo Electric Ind Ltd アダプター二本鎖ｄｎａ及びそれを用いたｄｎａ増幅方法
AU2733997A (en) 1996-04-17 1997-11-07 Du Pont Pharmaceuticals Company N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
US6057100A (en) 1996-06-07 2000-05-02 Eos Biotechnology, Inc. Oligonucleotide arrays
WO1998000134A1 (en) 1996-06-28 1998-01-08 Merck & Co., Inc. Fibrinogen receptor antagonists
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
US6207669B1 (en) 1996-07-13 2001-03-27 Glaxo Wellcome Inc. Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
DK0912559T3 (da) 1996-07-13 2003-03-10 Glaxo Group Ltd Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
JPH10147524A (ja) 1996-09-20 1998-06-02 Nippon Kayaku Co Ltd フォルスコリン誘導体含有経口製剤及び医薬製剤の製法
ATE300521T1 (de) 1996-09-25 2005-08-15 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
CN1072657C (zh) 1996-09-30 2001-10-10 日本农药株式会社 1,2,3－噻二唑衍生物和其盐以及农业园艺病毒防治剂及其使用方法
JPH10114655A (ja) 1996-10-09 1998-05-06 Kyowa Hakko Kogyo Co Ltd 固形製剤
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
WO1998023613A1 (en) 1996-11-27 1998-06-04 Pfizer Inc. Fused bicyclic pyrimidine derivatives
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
CA2275777A1 (en) 1997-01-29 1998-07-30 Louise Richman Levine Treatment for premenstrual dysphoric disorder
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP3040486U (ja) 1997-02-13 1997-08-19 有限会社ザップ フィッシングジャケット
ATE345339T1 (de) 1997-02-19 2006-12-15 Berlex Lab N-heterocyclische derivate als nos inhibitoren
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
JPH10316576A (ja) 1997-05-13 1998-12-02 Nissui Pharm Co Ltd キトサン含有錠剤
WO1998052558A1 (en) 1997-05-23 1998-11-26 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS
EP1078925A1 (en) 1997-06-10 2001-02-28 Synthon B.V. 4-Phenylpiperidine compounds
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
AU8283898A (en) 1997-06-30 1999-01-25 University Of Maryland At Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
JP3765918B2 (ja) 1997-11-10 2006-04-12 パイオニア株式会社 発光ディスプレイ及びその駆動方法
JP4194678B2 (ja) 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
WO1999032110A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING ARYL AND HETEROARYL SUBSTITUTED HETEROCYCLIC UREAS
ES2154253T3 (es) 1997-12-22 2012-01-27 Bayer Healthcare Llc Inhibición de la actividad de p38 cinasa usando ureas heterocíclicas sustituidas.
CZ299156B6 (cs) 1997-12-22 2008-05-07 Bayer Corporation Substituované heterocyklické mocoviny, farmaceutické prípravky je obsahující a jejich použití
TR200002616T2 (tr) 1997-12-22 2000-11-21 Bayer Corporation Simetrik ve simetrik olmayan sübstitüe edilmiş difenil üreler kullanılarak raf kinazın inhibe edilmesi
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO1999043654A2 (en) 1998-02-25 1999-09-02 Genetics Institute, Inc. Inhibitors of phospholipase enzymes
JP2002505269A (ja) 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
DE19814257A1 (de) 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
JPH11322596A (ja) 1998-05-12 1999-11-24 Shionogi & Co Ltd 白金錯体および環状リン酸エステルアミドを含有する抗癌剤
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
EP1087960B1 (en) 1998-06-17 2011-03-23 Eisai R&D Management Co., Ltd. Macrocyclic analogs and methods of their use and preparation
BR9914251A (pt) 1998-10-01 2001-06-19 Novartis Ag Formulações orais de liberação sustentada
NZ527718A (en) 1998-11-19 2004-11-26 Warner Lambert Co N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
ES2208261T3 (es) 1999-01-22 2004-06-16 Kirin Beer Kabushiki Kaisha Derivados de quinolina y derivados de quinazolina.
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
KR100838617B1 (ko) 1999-02-10 2008-06-16 아스트라제네카 아베 혈관형성 억제제로서의 퀴나졸린 유도체
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
JP2000328080A (ja) 1999-03-12 2000-11-28 Shin Etsu Chem Co Ltd シートベルト用低摩擦化処理剤
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU4778500A (en) 1999-05-20 2000-12-12 Takeda Chemical Industries Ltd. Composition containing ascorbic acid salt
JP4304357B2 (ja) 1999-05-24 2009-07-29 独立行政法人理化学研究所 完全長ｃＤＮＡライブラリーの作成法
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
JP2001047890A (ja) 1999-08-06 2001-02-20 Toyota Motor Corp 車両用パワープラントの制御装置
AU6762400A (en) 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
GT200000158A (es) 1999-09-28 2002-03-16 Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis.
US6762180B1 (en) 1999-10-13 2004-07-13 Boehringer Ingelheim Pharma Kg Substituted indolines which inhibit receptor tyrosine kinases
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
JP2001131071A (ja) 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd 非晶質および非晶質を含有する医薬組成物
US20080241835A1 (en) 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
JP2003525595A (ja) 1999-11-01 2003-09-02 キュラゲン コーポレイション 脈管形成に含まれる差動発現遺伝子、それにコードされるポリペプチド、及びそれを用いた方法
US6492393B1 (en) 1999-11-16 2002-12-10 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as anti-inflammatory agents
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
DK1255536T3 (da) 1999-12-22 2006-10-30 Sugen Inc Indolinonderivater til modulation af c-kit-tyrosinproteinkinase
EP1243582A4 (en) 1999-12-24 2003-06-04 Kirin Brewery CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
WO2001047931A1 (fr) 1999-12-24 2001-07-05 Kyowa Hakko Kogyo Co., Ltd. Derives de purine fondue
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
JP3657203B2 (ja) 2000-04-21 2005-06-08 エーザイ株式会社 銅クロロフィリン塩含有液剤組成物
CN1116047C (zh) 2000-06-05 2003-07-30 华中科技大学 用泥鳅制成的护肝功能食品及其制备方法
CA2411278A1 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
KR100600550B1 (ko) 2000-10-20 2006-07-13 에자이 가부시키가이샤 질소 함유 방향환 유도체
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
WO2002041882A2 (en) 2000-11-22 2002-05-30 Novartis Ag Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity
EP1341771A2 (en) 2000-11-29 2003-09-10 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US6544552B2 (en) 2001-01-11 2003-04-08 Particle And Coating Technologies, Inc. Method of producing porous tablets with improved dissolution properties
CA2439402A1 (en) 2001-03-02 2002-09-12 University Of Pittsburgh Of The Commonwealth System Of Higher Education Pcr method
EP1490362A2 (en) 2001-03-08 2004-12-29 Millennium Pharmaceuticals, Inc. (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases
IL157898A0 (en) 2001-04-06 2004-03-28 Wyeth Corp Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
EP1379545A2 (de) 2001-04-19 2004-01-14 Gesellschaft für biotechnologische Forschung mbH (GBF) Verfahren zur herstellung stabiler, regenerierbarer antikörper-arrays
PL209822B1 (pl) 2001-04-27 2011-10-31 Kirin Pharma Kk Pochodna chinoliny lub chinazoliny, zawierająca ją kompozycja farmaceutyczna i zastosowanie
JP3602513B2 (ja) 2001-04-27 2004-12-15 麒麟麦酒株式会社 アゾリル基を有するキノリン誘導体およびキナゾリン誘導体
JP2003026576A (ja) 2001-05-09 2003-01-29 Eisai Co Ltd 味覚改善製剤
US6812341B1 (en) 2001-05-11 2004-11-02 Ambion, Inc. High efficiency mRNA isolation methods and compositions
PL392652A1 (pl) 2001-05-16 2010-12-06 Novartis Ag Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
US6599902B2 (en) 2001-05-30 2003-07-29 Sugen, Inc. 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors
CN100415720C (zh) 2001-06-22 2008-09-03 麒麟医药株式会社 喹啉衍生物和喹唑啉衍生物以及含有这些化合物的药物组合物
GB0117144D0 (en) 2001-07-13 2001-09-05 Glaxo Group Ltd Process
US20030013208A1 (en) 2001-07-13 2003-01-16 Milagen, Inc. Information enhanced antibody arrays
JP4827154B2 (ja) 2001-07-25 2011-11-30 株式会社オーイズミ 遊技装置
JP3088018U (ja) 2001-08-02 2002-08-30 ユーエス工業株式会社 垂木支持用ブラケットを備えたパイプバンド
GB0119467D0 (en) 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
CA2459893C (en) 2001-09-10 2014-01-21 Meso Scale Technologies, Llc Methods and apparatus for conducting multiple measurements on a sample
DE60228278D1 (de) 2001-09-20 2008-09-25 Ab Science Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung
US6765012B2 (en) 2001-09-27 2004-07-20 Allergan, Inc. 3-(Arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors
WO2003028711A2 (en) 2001-09-27 2003-04-10 Novartis Ag Use of c-kit inhibitors for the treatment of myeloma
EP1435959A2 (en) 2001-10-09 2004-07-14 University of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
KR20050044599A (ko) 2001-11-27 2005-05-12 와이어쓰 홀딩스 코포레이션 Ｅｇｆ-ｒ 및 ｈｅｒ2 키나아제의 억제제로서의3-시아노퀴놀린
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
JP2005526506A (ja) 2002-03-04 2005-09-08 イムクローン システムズ インコーポレイティド Ｋｄｒに特異的なヒト抗体及びその利用
JP2003252737A (ja) 2002-03-04 2003-09-10 Shin Etsu Chem Co Ltd 口腔用組成物
WO2003074045A1 (fr) 2002-03-05 2003-09-12 Eisai Co., Ltd. Agent antitumoral comprenant une combinaison d'un compose heterocyclique contenant un sulfamide et d'un inhibiteur d'angiogenese
CN100337630C (zh) 2002-03-12 2007-09-19 布里斯托尔-迈尔斯斯奎布公司 可口的口服悬浮液及其制备方法
JP2005520834A (ja) 2002-03-20 2005-07-14 ダナ−ファーバー　キャンサー　インスティテュート，インコーポレイテッド 小細胞肺癌の同定、診断、および治療のための方法および組成物
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
AU2003235838A1 (en) 2002-05-01 2003-11-17 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004006862A2 (en) 2002-07-16 2004-01-22 Children's Medical Center Corporation A method for the modulation of angiogenesis
KR20050037557A (ko) 2002-07-22 2005-04-22 아스펜 에어로겔, 인코퍼레이티드 폴리이미드 에어로겔, 탄소 에어로겔 및 금속 카바이드에어로겔, 및 이들의 제조방법
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7252976B2 (en) 2002-08-28 2007-08-07 Board Of Regents The University Of Texas System Quantitative RT-PCR to AC133 to diagnose cancer and monitor angiogenic activity in a cell sample
CA2488739A1 (en) 2002-08-30 2004-03-11 Eisai Co., Ltd. Nitrogen-containing aromatic derivatives
BR0315169A (pt) 2002-10-09 2005-08-23 Kosan Biosciences Inc Referência cruzada a pedidos de patente relacionados
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
EP1556356B1 (en) 2002-10-21 2006-05-31 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as crth2 antagonists
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
DE10250711A1 (de) 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
WO2004041308A1 (en) 2002-11-06 2004-05-21 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ITSV20020056A1 (it) 2002-11-14 2004-05-15 Alstom Transp Spa Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
AR042042A1 (es) 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
ITMI20022447A1 (it) 2002-11-19 2004-05-20 Carlo Ghisalberti Uso di piridinoni nel trattamento della purpura capillare ed affezioni cutanee correlate.
KR20050100615A (ko) 2003-01-14 2005-10-19 싸이토키네틱스, 인코포레이티드 화합물, 조성물 및 방법
JP3581361B1 (ja) 2003-02-17 2004-10-27 株式会社脳機能研究所 脳活動測定装置
US20040162333A1 (en) 2003-02-19 2004-08-19 Naima Mezaache Rapid absorption selective 5-HT agonist formulations
MXPA05009063A (es) 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
BRPI0408005A (pt) 2003-03-05 2006-02-14 Celgene Corp composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
MXPA05009771A (es) 2003-03-14 2005-10-26 Ono Pharmaceutical Co Derivados heterociclicos que contienen nitrogeno y medicamentos que los contienen como el ingrediente activo.
US7435590B2 (en) 2003-03-14 2008-10-14 Taisho Pharmaceutical Co., Ltd. Monoclonal antibody and hybridoma producing the same
WO2004087096A1 (en) * 2003-04-02 2004-10-14 Pliva-Istrazivanje I Razvoj D.O.O. Pharmaceutical compositions having reduced bitter taste
US20050014753A1 (en) 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
WO2004101526A1 (ja) 2003-04-22 2004-11-25 Eisai Co., Ltd. ４－（３－クロロ－４－（シクロプロピルアミノカルボニル）アミノフェノキシ）－７－メトキシ－６－キノリンカルボキサミドの多形結晶及びその製造方法
KR100503949B1 (ko) 2003-04-28 2005-07-26 주식회사유한양행 염산 온단세트론의 쓴맛을 효과적으로 은폐한 경구용 구강속붕해정 조성물
EP1473043A1 (en) 2003-04-29 2004-11-03 Boehringer Ingelheim Pharma GmbH & Co.KG Pharmaceutical combination for the treatment of diseases involving cell proliferation, migration or apotosis of myeloma cells, or angiogenesis
US7107104B2 (en) 2003-05-30 2006-09-12 Medtronic, Inc. Implantable cortical neural lead and method
JP2005008534A (ja) 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法
CA2531862C (en) 2003-07-10 2011-10-25 Astrazenca Ab Use of the quinazoline derivative zd6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
EP1653934B1 (en) 2003-08-15 2008-05-14 AB Science Use of c-kit inhibitors for treating type ii diabetes
US7485658B2 (en) 2003-08-21 2009-02-03 Osi Pharmaceuticals, Inc. N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors
AU2004268949A1 (en) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. N-substituted benzimidazolyl C-kit inhibitors
AP2006003553A0 (en) 2003-08-21 2006-04-30 Osi Pharm Inc N-substituted pyrazolyl-amidyl-benzimidazolyl C- kit inhibitors.
US7312243B1 (en) 2003-08-29 2007-12-25 Jay Pravda Materials and methods for treatment of gastrointestinal disorders
US20080085902A1 (en) 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
EP2612853A1 (en) 2003-09-26 2013-07-10 Exelixis Inc. c-Met modulators and methods of use
KR200340552Y1 (ko) 2003-10-08 2004-02-11 주식회사 엘지화학 창틀 내부에 블라인드 및 방범창 설치가 용이한 이중창틀
JP2005124034A (ja) 2003-10-20 2005-05-12 Nippon Telegr & Teleph Corp <Ntt> 発信者の特定及び発信者への呼び返しを可能とする回線設定方法
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
EP1689376A2 (en) 2003-11-28 2006-08-16 Novartis AG Diaryl urea derivatives in the treatment of protein kinase dependent diseases
US6984403B2 (en) 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
RS54033B1 (en) 2003-12-25 2015-10-30 Eisai R&D Management Co. Ltd. CRYSTAL FORM OF THE SALTS 4- (3-CHLORO-4- (CYCLOPROPYLAMINOCARBONYL) AMINO-PHENOXY) -7-METHOXY-6-HINOLINKARBOXAMIDE OR ITS SOLVATES AND THE PROCESS FOR THEIR PRODUCTION
TW200536851A (en) 2004-01-23 2005-11-16 Amgen Inc Compounds and methods of use
EP1719762B1 (en) 2004-02-27 2012-06-27 Eisai R&D Management Co., Ltd. Novel pyridine derivative and pyrimidine derivative (1)
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
DK1753723T3 (da) 2004-05-21 2008-10-20 Novartis Vaccines & Diagnostic Substituerede quinolinderivater som mitotiske kinesininhibitorer
KR100986945B1 (ko) 2004-06-03 2010-10-12 에프. 호프만-라 로슈 아게 젬시타빈 및 ｅｇｆｒ-억제제로의 치료
EP1766407A2 (en) * 2004-06-18 2007-03-28 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20050288521A1 (en) 2004-06-29 2005-12-29 Phytogen Life Sciences Inc. Semi-synthetic conversion of paclitaxel to docetaxel
WO2006014325A2 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US7306807B2 (en) 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
EP2364699A1 (en) 2004-09-13 2011-09-14 Eisai R&D Management Co., Ltd. Joint use of sulfonamide based compound with angiogenesis inhibitor
WO2006030826A1 (ja) * 2004-09-17 2006-03-23 Eisai R & D Management Co., Ltd. 医薬組成物
EP1794137A4 (en) 2004-09-27 2009-12-02 Kosan Biosciences Inc SPECIFIC KINASE INHIBITORS
AU2005290583A1 (en) 2004-10-01 2006-04-13 Eisai R & D Management Co., Ltd. Fine particles-containing composition and manufacturing method therefor
BRPI0518209A (pt) 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
WO2007040565A2 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
DK1701722T3 (da) 2004-11-23 2010-01-11 Dong Wha Pharm Co Ltd N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
CN100341504C (zh) 2004-12-01 2007-10-10 鲁南制药集团股份有限公司 佐米曲普坦速释制剂
EP1824843A2 (en) 2004-12-07 2007-08-29 Locus Pharmaceuticals, Inc. Inhibitors of protein kinases
RS52036B (en) 2004-12-21 2012-04-30 Medimmune Limited ANGIOPOETIN-2 ANTIBODIES AND ITS USES
US20060198885A1 (en) 2005-02-22 2006-09-07 Sun Pharmaceutical Industries Ltd. Oral pharmaceutical composition
JP2006230816A (ja) 2005-02-25 2006-09-07 H & A Investment:Kk サンダル用ホルダー
WO2006090931A1 (ja) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. スルホンアミド化合物の抗癌剤との新規併用
SI1859793T1 (sl) 2005-02-28 2011-08-31 Eisai R&D Man Co Ltd Nova kombinirana uporaba sulfonamidne spojine za zdravljenje raka
US20080286282A1 (en) 2005-02-28 2008-11-20 Eisai R & D Management Co., Ltd. Novel Use of Sulfonamide Compound in Combination with Angiogenesis Inhibitor
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
NZ563444A (en) 2005-05-17 2011-04-29 Plexxikon Inc Pyrrolo(2,3-b)pyridine derivatives as protein kinase inhibitors
SI1883397T1 (sl) 2005-05-17 2010-04-30 Actelion Pharmaceuticals Ltd Disperzibilne tablete bosertana
NZ565255A (en) 2005-06-22 2010-04-30 Plexxikon Inc Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors
CA2606719C (en) 2005-06-23 2010-08-10 Eisai R & D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
EP1926494A2 (en) 2005-06-29 2008-06-04 Carlo Pedone Agonistic and antagonistic peptide mimetics of the vegf alpha-helix binding region for use in therapy
AU2006230974C1 (en) 2005-07-11 2012-02-02 Takeda Pharma A/S Benzimidazole formulation
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US20080219977A1 (en) 2005-07-27 2008-09-11 Isaiah Josh Fidler Combinations Comprising Gemcitabine and Tyrosine Kinase Inhibitors for the Treatment of Pancreatic Cancer
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007023768A1 (ja) 2005-08-24 2007-03-01 Eisai R & D Management Co., Ltd. 新規ピリジン誘導体およびピリミジン誘導体（３）
CN102716490A (zh) 2005-09-01 2012-10-10 卫材R&D管理有限公司 药物组合物的崩解性的改善方法
CN1308012C (zh) 2005-11-02 2007-04-04 广州中医药大学第二附属医院 一种治疗脑出血的中药组合物及其制备方法
JPWO2007052849A1 (ja) 2005-11-07 2009-04-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質とｃ−ｋｉｔキナーゼ阻害物質との併用
US20090247576A1 (en) 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
SI1959955T1 (sl) 2005-12-05 2011-02-28 Pfizer Prod Inc Postopek zdravljenja abnormalne celične rasti
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007109057A2 (en) 2006-03-16 2007-09-27 Novartis Ag Solid dosage form containing a taste masked active agent
KR100728926B1 (ko) 2006-03-20 2007-06-15 삼성전자주식회사 3축 힌지 구조를 갖는 휴대용 전자기기
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
ATE535520T1 (de) 2006-08-23 2011-12-15 Eisai R&D Man Co Ltd Salz eines phenoxypyridinderivats oder kristall davon und verfahren zu dessen herstellung
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
CA2662591A1 (en) 2006-09-07 2008-03-13 Astrazenca Ab Method for evaluating patients for treatment with drugs targeting ret receptor tyrosine kinase
RS54025B1 (en) 2006-10-12 2015-10-30 Ptc Therapeutics Inc. DOSAGE PROCEDURES FOR ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR NONSENS MUTATION SUPPRESSION THERAPY
JP2009184925A (ja) * 2006-11-02 2009-08-20 Dai Ichi Seiyaku Co Ltd ５−（１ｈ−１，２，３−トリアゾール−４−イル）−１ｈ−ピラゾール誘導体
WO2008089459A1 (en) 2007-01-19 2008-07-24 Ardea Biosciences, Inc. Inhibitors of mek
AU2008205847A1 (en) 2007-01-19 2008-07-24 Eisai R & D Management Co., Ltd. Composition for treatment of pancreatic cancer
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
JPWO2008102870A1 (ja) 2007-02-23 2010-05-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｈｇｆｒ遺伝子増幅細胞株に優れた細胞増殖阻害効果および抗腫瘍効果を示すピリジン誘導体またはピリミジン誘導体
EP2133095A4 (en) 2007-03-05 2012-09-26 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
EP2133094A4 (en) 2007-03-05 2010-10-13 Kyowa Hakko Kirin Co Ltd PHARMACEUTICAL COMPOSITION
GB2448181B (en) 2007-04-05 2011-11-09 Ford Global Tech Llc Vehicle headlight beam controls
US7807172B2 (en) 2007-06-13 2010-10-05 University Of Washington Methods and compositions for detecting thyroglobulin in a biological sample
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
CA2713930A1 (en) 2008-01-29 2009-08-06 Eisai R & D Management Co., Ltd. Combined use of angiogenesis inhibitor and taxane
GB2456907A (en) 2008-01-30 2009-08-05 Astrazeneca Ab Method for determining subsequent VEGFR2 inhibitor therapy comprising measuring baseline VEGF level.
EP2259844A4 (en) 2008-03-05 2012-02-01 Vicus Therapeutics Llc COMPOSITIONS AND METHODS FOR MUCOSITIS AND ONCOLOGY THERAPIES
US8044240B2 (en) 2008-03-06 2011-10-25 Ardea Biosciences Inc. Polymorphic form of N-(S)-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide and uses thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
WO2009129246A2 (en) 2008-04-14 2009-10-22 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
JP2009263298A (ja) 2008-04-28 2009-11-12 Ss Pharmaceut Co Ltd 不快な味を隠ぺいした経口組成物
US8637554B2 (en) 2008-05-07 2014-01-28 The Trustees Of The University Of Pennsylvania Methods for treating thyroid cancer
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
WO2009150255A2 (en) 2008-06-13 2009-12-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Markers for predicting response and survival in anti-egfr treated patients
MX336723B (es) 2008-07-11 2016-01-28 Novartis Ag Combinacion de (a) un inhibidor de fosfoinositido 3-cinasa y (b) un modulador de la ruta de ras/raf/mek.
WO2010048304A2 (en) 2008-10-21 2010-04-29 Bayer Healthcare Llc Identification of signature genes associated with hepatocellular carcinoma
WO2010086964A1 (ja) 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
CA2770307A1 (en) 2009-08-07 2011-02-10 The Wistar Institute Compositions containing jarid1b inhibitors and methods for treating cancer
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
WO2011022335A1 (en) 2009-08-21 2011-02-24 Mount Sinai School Of Medicine Of New York University Methods of using cd44 fusion proteins to treat cancer
EP2293071A1 (en) 2009-09-07 2011-03-09 Universität Zu Köln Biomarker for colorectal cancer
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
EP2594566A4 (en) 2010-07-16 2014-10-01 Kyowa Hakko Kirin Co Ltd AROMATIC HETEROCYCLIC NITROGEN CYCLE DERIVATIVE
MX2013000667A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer.
MX2013000672A (es) 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar un paciente con probabilidad incrementada de responder a una terapia anti-cancer.
WO2012010546A1 (en) 2010-07-19 2012-01-26 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
SG187013A1 (en) 2010-07-19 2013-02-28 Hoffmann La Roche Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
WO2012019300A1 (en) 2010-08-10 2012-02-16 Siu K W Michael Endometrial cancer biomarkers and methods of identifying and using same
JP5259880B2 (ja) 2010-09-01 2013-08-07 興和株式会社 経口剤
US20120077837A1 (en) 2010-09-24 2012-03-29 Eisai R&D Management Co., Ltd. Anti-tumor agent
AU2012223639B2 (en) 2011-02-28 2015-03-19 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
WO2012119095A1 (en) 2011-03-02 2012-09-07 Board Of Regents, The University Of Texas System Fus1/tusc2 therapies
US9107887B2 (en) 2011-03-10 2015-08-18 Provectus Pharmaceuticals, Inc. Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer
AU2012246490B2 (en) 2011-04-18 2016-08-04 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012154935A1 (en) 2011-05-12 2012-11-15 Eisai R&D Management Co., Ltd. Biomarkers that are predictive of responsiveness or non-responsiveness to treatment with lenvatinib or a pharmaceutically acceptable salt thereof
JP5952810B2 (ja) 2011-05-17 2016-07-13 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤の効果を予測する方法
EP2714937B1 (en) 2011-06-03 2018-11-14 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CA2864322C (en) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. High-content fast dissolving film with masking of bitter taste comprising sildenafil as active ingredient
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
SG11201407190TA (en) 2012-05-15 2014-12-30 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
JP2015517511A (ja) 2012-05-16 2015-06-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３７抗体とｉｃｅ（イフォスファミド、カルボプラチン、エトポシド）の併用
KR102130865B1 (ko) 2012-10-02 2020-08-05 브리스톨-마이어스 스큅 컴퍼니 암을 치료하기 위한 항-kir 항체와 항-pd-1 항체의 조합물
MX2015007185A (es) 2012-12-04 2017-09-05 Eisai R&D Man Co Ltd Uso de eribulina en el tratamiento de cancer de pecho.
US10980804B2 (en) 2013-01-18 2021-04-20 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
UA114950C2 (uk) 2013-02-28 2017-08-28 Ейсей Р Енд Д Менеджмент Ко., Лтд. ТЕТРАГІДРОІМІДАЗО[1,5-d][1,4]ОКСАЗЕПІНОВА ПОХІДНА
JP6411379B2 (ja) 2013-05-14 2018-10-24 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する子宮内膜がん対象の応答性を予測及び評価するためのバイオマーカー
RU2672585C2 (ru) 2013-06-26 2018-11-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Применение эрибулина и ленватиниба в качестве комбинированной терапии для лечения рака
US9174998B2 (en) 2013-12-25 2015-11-03 Eisai R&D Management Co., Ltd. (6S,9aS)-N-benzyl-6-[(4-hydroxyphenyl)methyl]-4,7-dioxo-8-({6-[3-(piperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-2-(prop-2-en-1-yl)-octahydro-1H-pyrazino[2,1-c][1,2,4]triazine-1-carboxamide compound
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
AU2015214404B2 (en) 2014-02-04 2020-10-01 Incyte Corporation Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
ES2926687T3 (es) 2014-08-28 2022-10-27 Eisai R&D Man Co Ltd Derivado de quinolina muy puro y método para su producción
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
RU2723551C2 (ru) 2015-06-23 2020-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Кристалл (6S,9aS)-N-бензил-8-({ 6-[3-(4-этилпиперазин-1-ил)азетидин-1-ил]пиридин-2-ил} метил)-6-(2-фтор-4-гидроксибензил)-4,7-диоксо-2-(проп-2-ен-1-ил)гексагидро-2H-пиразино[2,1-c][1,2,4]триазин-1(6H)-карбоксамида
US20200375975A1 (en) 2016-04-15 2020-12-03 Eisai R&D Management Co., Ltd. Treatment of Renal Cell Carcinoma with Lenvatinib and Everolimus

Also Published As

Publication number Publication date
CN107427505A (zh) 2017-12-01
IL253946A0 (en) 2017-10-31
HUE064614T2 (hu) 2024-04-28
PT3263106T (pt) 2024-01-12
US20180028662A1 (en) 2018-02-01
SG11201706630UA (en) 2017-09-28
ES2967362T3 (es) 2024-04-29
US20180318422A1 (en) 2018-11-08
FI3263106T3 (fi) 2024-01-03
AU2016224583B2 (en) 2021-06-03
CA2976325A1 (en) 2016-09-01
WO2016136745A1 (ja) 2016-09-01
KR20170122734A (ko) 2017-11-06
DK3263106T3 (da) 2024-01-08
JP6792546B2 (ja) 2020-11-25
RU2017128583A (ru) 2019-03-25
SI3263106T1 (sl) 2024-02-29
US11090386B2 (en) 2021-08-17
EP3263106A4 (en) 2018-08-29
RU2017128583A3 (hr) 2019-03-25
RS65049B1 (sr) 2024-02-29
CA2976325C (en) 2023-07-04
JPWO2016136745A1 (ja) 2017-11-30
EP3263106A1 (en) 2018-01-03
BR112017017428A2 (pt) 2018-04-03
MX2017010474A (es) 2017-11-28
LT3263106T (lt) 2024-01-10
PL3263106T3 (pl) 2024-04-02
EP3263106B1 (en) 2023-10-25
AU2016224583A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
HRP20231692T1 (hr) Postupak za suzbijanje gorčine derivata kinolina
HRP20240459T1 (hr) Režim za doziranje valbenazina za liječenje hiperkinetskih poremećaja pokreta
JP2016534142A5 (hr)
HRP20180018T1 (hr) Kombinacija agonista receptora 5-ht 4 i inhibitora acetilkolinesteraze za liječenje kognitivnog poremećaja
HRP20191366T4 (hr) Injekcijski pripravak
JP2016027060A5 (hr)
RU2713889C2 (ru) Пироглутамат вортиоксетина
CN108057036B (zh) 一种egfr抑制剂的固体药物组合物
RU2017143849A (ru) Твёрдый состав для перорального применения, содержащий иринотекан, и способ его получения
CA3147586A1 (en) Compositions and kits for omeprazole suspension
HRP20201844T1 (hr) Biodostupni poliamini
JPWO2013047725A1 (ja) Ｐｇｄ２拮抗剤及びヒスタミン拮抗剤からなるアレルギー性鼻炎治療用医薬
ES2588008T3 (es) Composición farmacéutica que contiene solifenacina
JP2021178868A (ja) 全自然非毒性舌下薬剤の送達システム
RU2017145602A (ru) Жидкие композиции целекоксиба для перорального введения
JP2015120758A5 (hr)
CN105193764A (zh) 一种阿戈美拉汀固体分散体及其制备方法
CN105902564A (zh) 一种治疗高血压的药物组合物及制备方法
Bafna Formulation and evaluation of taste masked oral suspension of chloroquine phosphate
EA201691763A1 (ru) Стабильная быстрорастворимая лекарственная форма, содержащая амоксициллин и клавулановую кислоту
NZ596881A (en) Phentermine liquid dosage form
FI3169311T3 (fi) Pediatrinen jauhe viruslääkettä sisältävää suun kautta annettavaa suspensiota varten ja menetelmä sen valmistamiseksi
CN108883074A (zh) 含有他达拉非和坦索罗辛并具有改善的稳定性和溶出率的复合胶囊制剂
CN104606136A (zh) 甲氧氯普胺鼻腔喷雾剂、其制备方法及用途
TR201613300A1 (tr) Anti̇muskari̇ni̇k farmasöti̇k terki̇pler